Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eliquis Delay Fuels Speculation About Advisory Committee Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Three-month user fee extension for Bristol-Myers Squibb and Pfizer’s novel oral anticoagulant apixaban raises questions about whether an advisory committee panel will be convened after all, though the companies say none has been scheduled at this time.

You may also be interested in...



New Drug News, In Brief

FDA approves Abbott’s Humira for ulcerative colitis and Bayer/Onyx’s regorafenib for colorectal cancer, Bristol-Myers Squibb/Pfizer’s Eliquis faces a St. Patrick’s Day user fee date, and an NEJM poll finds the medical community is evenly split over use of Gilead’s Truvada for HIV pre-exposure prophylaxis.

Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter

FDA could have concerns about the reported data from the ARISTOTLE trial, either from the bleeding comparisons or the dosing in the warfarin control arm. Missing data is another possible issue, as in the recent “complete response” letter for J&J/Bayer’s Xarelto.

Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter

FDA could have concerns about the reported data from the ARISTOTLE trial, either from the bleeding comparisons or the dosing in the warfarin control arm. Missing data is another possible issue, as in the recent “complete response” letter for J&J/Bayer’s Xarelto.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel